(Reuters) -Medical device maker Boston Scientific ( BSX ) said on Friday it will buy the remaining equity in privately held Nalu Medical for about $533 million in cash, expanding its treatments for chronic pain.

The deal gives Boston Scientific ( BSX ) access to Nalu's Neurostimulation System, which is designed to deliver targeted relief for adults living with chronic pain in areas such as the shoulder, lower back and knee, through peripheral nerve stimulation.

The therapy uses mild electrical impulses to interrupt pain signals before they reach the brain and features a miniaturized, battery-free implantable pulse generator, powered wirelessly by a small, externally worn therapy disc and controlled via a smartphone app.

Boston Scientific ( BSX ) has been a strategic investor in Nalu Medical since 2017. The transaction is expected to complete in the first half of 2026.